Finance

Lists
524731:BOM
Jenburkt Pharmaceuticals Ltd
₹916,00
+0,11%
(+1,00) 1D
15 Okt., 14:28:45 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for 524731...
Open
₹915,60
High
₹940,20
Low
₹915,60
Mkt. cap
4,68 mjd
Avg. vol.
461,00
Volume
104,00
P/E ratio
12,31
52-wk high
₹1 321,00
52-wk low
₹880,10
EPS
₹74,40
Shares outstanding
4,59 m
No. of employees
801
Open
₹915,60
High
₹940,20
Low
₹915,60
Mkt. cap
4,68 mjd
Avg. vol.
461,00
Volume
104,00
P/E ratio
12,31
52-wk high
₹1 321,00
52-wk low
₹880,10
EPS
₹74,40
Shares outstanding
4,59 m
No. of employees
801
News stories
From web sources and news partners
About Jenburkt Pharmaceuticals Ltd
CEO-
Employees801
Founded1985
Headquarters-
SectorPharmaceutical industry
Last report
06 Aug. 2026
Fiscal period
Q1 2027
- / -
Revenue / Est. (INR)
355,12 m / -
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
455,58 m
430,24 m
446,32 m
355,12 m
Cost of goods sold
83,56 m
87,89 m
101,21 m
63,22 m
Cost of revenue
83,56 m
87,89 m
101,21 m
63,22 m
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
139,32 m
147,14 m
95,15 m
130,25 m
Operating expense
248,41 m
276,38 m
191,98 m
238,04 m
Total operating expenses
331,97 m
364,27 m
293,19 m
301,26 m
Operating income
123,60 m
65,97 m
153,13 m
53,86 m
Other non operating income
20,79 m
18,15 m
-60,40 m
15,13 m
EBT including unusual items
143,32 m
82,97 m
137,08 m
67,69 m
EBT excluding unusual items
143,32 m
82,97 m
171,23 m
67,69 m
Income tax expense
41,69 m
23,65 m
28,59 m
8,84 m
Effective tax rate
29,09%
28,51%
20,85%
13,05%
Other operating expenses
101,64 m
120,92 m
88,74 m
101,38 m
Net income
101,63 m
59,31 m
108,49 m
58,86 m
Net profit margin
22,31%
13,79%
24,31%
16,57%
Earnings per share
-
-
-
-
Interest and investment income
-
-
57,47 m
-
Interest expense
-1,07 m
-1,16 m
-392,00 k
-1,30 m
Net interest expenses
-1,07 m
-1,16 m
57,07 m
-1,30 m
Depreciation and amortization charges
7,44 m
8,32 m
8,09 m
6,41 m
EBITDA
130,94 m
71,11 m
158,72 m
59,45 m
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google-programme